BrainsWay Ltd. (TLV: BWAY)
Market Cap | 631.55M |
Revenue (ttm) | 143.60M |
Net Income (ttm) | 5.58M |
Shares Out | 37.59M |
EPS (ttm) | 0.16 |
PE Ratio | 102.30 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 31,158 |
Open | 1,684.00 |
Previous Close | 1,684.00 |
Day's Range | 1,653.00 - 1,684.00 |
52-Week Range | 934.70 - 2,056.00 |
Beta | 0.38 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Mar 20, 2025 |
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, East Asia, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves do... [Read more]
Financial Performance
In 2023, BrainsWay's revenue was $31.79 million, an increase of 16.96% compared to the previous year's $27.18 million. Losses were -$4.20 million, -68.56% less than in 2022.
Financial numbers in USD Financial StatementsNews
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain ...
BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy
BURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd.
BrainsWay: Cash Flow Doubts Weigh On The Stock
BrainsWay reported strong growth in the third quarter and gave solid guidance. Click here to read my analysis of BWAY stock.
BrainsWay Ltd. (BWAY) Q3 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call P...
BrainsWay Reports Third Quarter 2024 Financial Results and Operational Highlights
Robust 26% Year-over-Year Revenue Growth in Q3 2024 Raising Full-Year 2024 Revenue Guidance to $40-41 Million and Initiating Profitability Guidance Conference Call to be Held Today at 8:30 AM ET BURLI...
Earnings Scheduled For November 12, 2024
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQ: TIGR) is likely to report quarterly earnings at $0.13 per share on revenue of $98.00 million. • PLDT (NYSE: PHI) is likely to report...
BrainsWay Q3 Earnings Preview
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
Are Medical Stocks Lagging Brainsway This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY) been one of thos...
BrainsWay Further Penetrates East Asia with Placement of 15 Additional Deep TMS™ Systems in Taiwan and South Korea
BURLINGTON, Mass. and JERUSALEM, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation...
BrainsWay: More Cash, More Uncertainty
What's Going On With BrainsWay Shares Monday?
BrainsWay Ltd. (NASDAQ: BWAY) stock is trading higher on Monday after the company announced a $20 million investment from Valor Equity Partners. The Details: BrainsWay will issue a total of 2,103,745...
BrainsWay Announces US$20 Million Private Placement with Valor Equity Partners
Company to leverage capital and Valor's expertise for strategic initiatives building market awareness, R&D roadmap, data analysis capabilities, and expanding access to Deep TMS™
BrainsWay announces expansion of Deep TMS platform along East Coast
BrainsWay Announces Significant Expansion on U.S. East Coast
BURLINGTON, Mass. and JERUSALEM, Sept.
Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli Hospitals
BURLINGTON, Mass. and JERUSALEM, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio...
BrainsWay appoints Richard Bermudes, M.D. as CMO
BrainsWay (BWAY) has announced the appointment of Richard A. Bermudes, M.D. as Chief Medical Officer, effective Sept. 1, 2024
BrainsWay Appoints Richard A. Bermudes, M.D.
Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field Dr. Bermudes is Widely Considered One of the Preeminent U.S. Clinicians in the TMS Field
BrainsWay: Operating Leverage Driving Upside
BrainsWay Ltd. (BWAY) Q2 2024 Earnings Call Transcript
BrainsWay Ltd. (NASDAQ:BWAY) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Brian Ritchie - IR, LifeSci Advisors Hadar Levy - CEO Ido Marom - CFO Conference Call Part...
BrainsWay Reports Second Quarter 2024 Financial Results and Operational Highlights
Generated Robust 28 % Year-over-Year Revenue Growth in Q2 2024 Recorded Positive Quarterly Net Income for Third Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Four...
BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada
BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for Depression
Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™ Shortened Acute Treatment Period Could Enhance Appeal and Market Opportunities of Deep TMS™
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression
Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Treatment in Patients Between the Ages of 68 and 86 Deep TMS™ Becomes the First and Only TMS Device Indicated for Depression Tr...